# An Ascending Dose, Single/Multiple Dosing, Food Effect Clinical Trial to Evaluate Pharmacokinetics, Safety and Tolerability in Healthy Subjects After Oral Administration of Gemigliptin (Phase I)

> **NCT03864432** · PHASE1 · COMPLETED · sponsor: **LG Chem** · enrollment: 48 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Gemigliptin 25mg
- **DRUG:** Gemigliptin 50mg
- **DRUG:** Gemigliptin 100mg
- **DRUG:** Gemiglptin 50mg multiple dose

## Key facts

- **NCT ID:** NCT03864432
- **Lead sponsor:** LG Chem
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-02
- **Primary completion:** 2019-10-03
- **Final completion:** 2020-02-28
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2020-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03864432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03864432, "An Ascending Dose, Single/Multiple Dosing, Food Effect Clinical Trial to Evaluate Pharmacokinetics, Safety and Tolerability in Healthy Subjects After Oral Administration of Gemigliptin (Phase I)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03864432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*